BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27412324)

  • 21. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
    Zhou N; Xu X; Liu Y; Wang Y; Wei W
    Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
    Hashida N; Nakai K; Saitoh N; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
    Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
    J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INTRAVITREAL METHOTREXATE FOR MANTLE CELL LYMPHOMA INFILTRATION OF THE OPTIC NERVES: A CASE REPORT.
    Singer JR; Nigalye AK; Champion MT; Welch MJ
    Retin Cases Brief Rep; 2018 Winter; 12(1):5-9. PubMed ID: 27529778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic high-dose intravenous methotrexate for central nervous system metastases.
    Lassman AB; Abrey LE; Shah GD; Panageas KS; Begemann M; Malkin MG; Raizer JJ
    J Neurooncol; 2006 Jul; 78(3):255-60. PubMed ID: 16344918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
    Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
    Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
    Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
    Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
    Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
    Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of primary intraocular lymphoma with intravitreal methotrexate.
    Sou R; Ohguro N; Maeda T; Saishin Y; Tano Y
    Jpn J Ophthalmol; 2008; 52(3):167-174. PubMed ID: 18661266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
    Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
    J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection].
    Watanabe K; Arai A; Takase H; Takahashi H; Iwanaga Y; Sugamoto Y; Sugita S; Mochizuki M; Miura O
    Rinsho Ketsueki; 2009 Mar; 50(3):182-6. PubMed ID: 19352085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
    Motomura Y; Yoshifuji K; Tachibana T; Takase H; Arai A; Tanaka K; Okada K; Nogami A; Umezawa Y; Sakashita C; Yamamoto M; Mori T; Nagao T
    Br J Haematol; 2024 Apr; 204(4):1279-1287. PubMed ID: 38131400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
    Moe PJ; Holen A; Nygaard R; Glomstein A; Madsen B; Hellebostad M; Stokland T; Wefring KW; Steen-Johnsen J; Nielsen B; Hapnes C; Børsting S
    Pediatr Hematol Oncol; 2003; 20(3):187-200. PubMed ID: 12637215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
    Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
    Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.